-
Citizens JMP Reiterates Market Outperform Rating on CRISPR Therapeutics (CRSP)
-
CRISPR Therapeutics (CRSP) PT Lowered to $82 at Citi
-
CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
-
Citi Opens 30-Day Upside Catalyst Watch on CRISPR Therapeutics (CRSP)
-
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
-
Citi Upgrades CRISPR Therapeutics (CRSP) to Buy 'given shares have declined ~30% since May 2023'
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
-
Pre-Open Stock Movers 06/28: (NTLA) (AVXL) (EDIT) Higher; (GTEC) (XPO) (CCL) Lower (more...)
-
UPDATE: Citi Upgrades CRISPR Therapeutics (CRSP) to Neutral
-
Pre-Open Stock Movers 01/22: (EBAY) (UAA) (PANW) Higher; (ARNC) (PETS) (SWK) Lower (more...)
-
Citi Downgrades CRISPR Therapeutics (CRSP) to Sell
-
CRISPR/Vertex News Bodes Well or Fate Therapeutics (FATE) - Citi
-
CRISPR Therapeutics to Present at Upcoming Investor Conferences
-
CRISPR Therapeutics (CRSP) PT Lowered to $50 at Citi
-
CRISPR Therapeutics (CRSP) PT Raised to $51 at Citi
-
CRISPR Therapeutics (CRSP) PT Raised to $20 at Citi
-
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
-
Citi Starts CRISPR Therapeutics (CRSP) at Neutral
-
CRISPR Therapeutics AG (CRSP) IPO Opens Up 7%
-
CRISPR Therapeutics (CRSP) Prices 4M Common Stock IPO at $14/Share, Below Prior Expectations
-
CRISPR Therapeutics Announces Pricing of Initial Public Offering
-
CRISPR Therapeutics (CRSP) Sees IPO Price of $15 - $17/Share

